Skip to Content

Darolutamide (Nubeqa) in combination with Docetaxel (Taxotere) for Metastatic Hormone Sensitive Prostate Cancer

Download PQI pdf 0.18MB

Last Updated: November 14, 2023

By: Katie Snell, AGNP-C

About this PQI

This PQI aims to provide information on the administration and management of adverse events, patient follow-up, and recommended dose reductions for darolutamide in combination with docetaxel for metastatic hormone sensitive prostate cancer (mHSPC).

How to Use a Positive Quality Intervention (PQI)

Essentially, it’s a tool to improve patient care by sharing best practices in oncology care. Consider this standardized, peer-review clinical guidance to oncology healthcare teams, enabling you and your team to consistently deliver high-quality care to your patients.

Find a PQI